More than 160 leaders of biotechnology companies signed a strong letter of opposition to President Trump’s travel ban, arguing the ”poorly conceived and implemented” action strikes at the heart of an industry that originated in America, has been dominated by American companies, and is at the cutting edge of medicine. The letter, published Tuesday by the journal Nature Biotechnology, reveals that scientists abroad are afraid to come to the United States and are canceling trips.